Search

Ta Hsung Tung

Examiner (ID: 4022)

Most Active Art Unit
1102
Art Unit(s)
1744, 1104, 1753, 1106, 1102, 1743, 2899, 2701, 2901
Total Applications
1660
Issued Applications
1317
Pending Applications
54
Abandoned Applications
289

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 13944719 [patent_doc_number] => 10208115 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-19 [patent_title] => Amino acid sequences that modulate the interaction between cells of the immune system [patent_app_type] => utility [patent_app_number] => 15/050740 [patent_app_country] => US [patent_app_date] => 2016-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 148007 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15050740 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/050740
Amino acid sequences that modulate the interaction between cells of the immune system Feb 22, 2016 Issued
Array ( [id] => 15468621 [patent_doc_number] => 10550173 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-04 [patent_title] => PVRIG polypeptides and methods of treatment [patent_app_type] => utility [patent_app_number] => 15/048975 [patent_app_country] => US [patent_app_date] => 2016-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 223 [patent_figures_cnt] => 335 [patent_no_of_words] => 58535 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 281 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15048975 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/048975
PVRIG polypeptides and methods of treatment Feb 18, 2016 Issued
Array ( [id] => 10812158 [patent_doc_number] => 20160158318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'METHODS FOR TREATING SCLERODERMA BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE' [patent_app_type] => utility [patent_app_number] => 15/047849 [patent_app_country] => US [patent_app_date] => 2016-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 102 [patent_figures_cnt] => 102 [patent_no_of_words] => 49017 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15047849 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/047849
Methods for treating dermatomyositis or polymyositis by administering a soluble CTLA4 molecule Feb 18, 2016 Issued
Array ( [id] => 11419896 [patent_doc_number] => 20170028040 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'METHOD FOR ENHANCING IMMUNE RESPONSE IN THE TREATMENT OF INFECTIOUS AND MALIGNANT DISEASES' [patent_app_type] => utility [patent_app_number] => 15/044613 [patent_app_country] => US [patent_app_date] => 2016-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 7972 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15044613 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/044613
Method for enhancing immune response in the treatment of infectious and malignant diseases Feb 15, 2016 Issued
Array ( [id] => 11040198 [patent_doc_number] => 20160237154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-18 [patent_title] => 'ANTIBODY THERAPEUTICS THAT BIND CTLA4' [patent_app_type] => utility [patent_app_number] => 15/043157 [patent_app_country] => US [patent_app_date] => 2016-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 26545 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15043157 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/043157
Antibody therapeutics that bind CTLA4 Feb 11, 2016 Issued
Array ( [id] => 11866191 [patent_doc_number] => 20170233476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'Antibody Therapeutics That Bind CTLA4' [patent_app_type] => utility [patent_app_number] => 15/043269 [patent_app_country] => US [patent_app_date] => 2016-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 26548 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15043269 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/043269
Antibody Therapeutics That Bind CTLA4 Feb 11, 2016 Abandoned
Array ( [id] => 11053360 [patent_doc_number] => 20160250322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'VECTOR CO-EXPRESSING VACCINE AND COSTIMULATORY MOLECULES' [patent_app_type] => utility [patent_app_number] => 15/016375 [patent_app_country] => US [patent_app_date] => 2016-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 26871 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15016375 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/016375
Vector co-expressing vaccine and costimulatory molecules Feb 4, 2016 Issued
Array ( [id] => 11025164 [patent_doc_number] => 20160222119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-04 [patent_title] => 'ISOLATED B7-H4 SPECIFIC COMPOSITIONS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/009082 [patent_app_country] => US [patent_app_date] => 2016-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 34153 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15009082 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/009082
Isolated B7-H4 specific compositions and methods of use thereof Jan 27, 2016 Issued
Array ( [id] => 11018106 [patent_doc_number] => 20160215059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-28 [patent_title] => 'ICOS BINDING PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/006560 [patent_app_country] => US [patent_app_date] => 2016-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 51483 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15006560 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/006560
ICOS binding proteins Jan 25, 2016 Issued
Array ( [id] => 11784024 [patent_doc_number] => 09393301 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-07-19 [patent_title] => 'Immunopotentiative composition' [patent_app_type] => utility [patent_app_number] => 15/000863 [patent_app_country] => US [patent_app_date] => 2016-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 32 [patent_no_of_words] => 14068 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15000863 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/000863
Immunopotentiative composition Jan 18, 2016 Issued
Array ( [id] => 11210945 [patent_doc_number] => 09439962 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-13 [patent_title] => 'Immunopotentiative composition' [patent_app_type] => utility [patent_app_number] => 15/000869 [patent_app_country] => US [patent_app_date] => 2016-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 32 [patent_no_of_words] => 14075 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15000869 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/000869
Immunopotentiative composition Jan 18, 2016 Issued
Array ( [id] => 10799188 [patent_doc_number] => 20160145345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-26 [patent_title] => 'Human Anti-B7RP1 Neutralizing Antibodies' [patent_app_type] => utility [patent_app_number] => 14/995983 [patent_app_country] => US [patent_app_date] => 2016-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 25934 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14995983 [rel_patent_id] =>[rel_patent_doc_number] =>)
14/995983
Human anti-B7RP1 neutralizing antibodies Jan 13, 2016 Issued
Array ( [id] => 14145477 [patent_doc_number] => 10253097 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-09 [patent_title] => Isolated antibody [patent_app_type] => utility [patent_app_number] => 14/988938 [patent_app_country] => US [patent_app_date] => 2016-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 43 [patent_no_of_words] => 22761 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14988938 [rel_patent_id] =>[rel_patent_doc_number] =>)
14/988938
Isolated antibody Jan 5, 2016 Issued
Array ( [id] => 11054475 [patent_doc_number] => 20160251436 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'Anti-PD-1 Antibodies' [patent_app_type] => utility [patent_app_number] => 14/975769 [patent_app_country] => US [patent_app_date] => 2015-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 20117 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 20 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14975769 [rel_patent_id] =>[rel_patent_doc_number] =>)
14/975769
Anti-PD-1 antibodies Dec 18, 2015 Issued
Array ( [id] => 12118836 [patent_doc_number] => 20180002422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'METHODS FOR UPREGULATING IMMUNE RESPONSES USING COMBINATIONS OF ANTI-RGMb AND ANTI-PD-1 AGENTS' [patent_app_type] => utility [patent_app_number] => 15/533532 [patent_app_country] => US [patent_app_date] => 2015-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 52969 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15533532 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/533532
Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents Dec 6, 2015 Issued
Array ( [id] => 10813767 [patent_doc_number] => 20160159927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V-R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 14/960973 [patent_app_country] => US [patent_app_date] => 2015-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 95182 [patent_no_of_claims] => 51 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14960973 [rel_patent_id] =>[rel_patent_doc_number] =>)
14/960973
Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists Dec 6, 2015 Issued
Array ( [id] => 10813745 [patent_doc_number] => 20160159905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/958053 [patent_app_country] => US [patent_app_date] => 2015-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 55062 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14958053 [rel_patent_id] =>[rel_patent_doc_number] =>)
14/958053
Anti-PD-1 antibodies and methods of use thereof Dec 2, 2015 Issued
Array ( [id] => 11785020 [patent_doc_number] => 09394365 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2016-07-19 [patent_title] => 'Reducing systemic regulatory T cell levels or activity for treatment of alzheimer\'s disease' [patent_app_type] => utility [patent_app_number] => 14/957065 [patent_app_country] => US [patent_app_date] => 2015-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 56 [patent_no_of_words] => 21366 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14957065 [rel_patent_id] =>[rel_patent_doc_number] =>)
14/957065
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease Dec 1, 2015 Issued
14/955843 Antibodies, Uses & Methods Nov 30, 2015 Abandoned
Array ( [id] => 13106899 [patent_doc_number] => 10072082 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-11 [patent_title] => Cancer immunotherapy by disrupting PD-1/PD-L1 signaling [patent_app_type] => utility [patent_app_number] => 14/950748 [patent_app_country] => US [patent_app_date] => 2015-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 39748 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 222 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14950748 [rel_patent_id] =>[rel_patent_doc_number] =>)
14/950748
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Nov 23, 2015 Issued
Menu